Vivimed Labs Limited has announced the resignation of its Chief Financial Officer, Mr. Phaninder Nath P S, effective February 06, 2026. The pharmaceutical company informed stock exchanges about this key management change through a regulatory filing under SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Resignation Details

The company disclosed that Mr. Phaninder Nath P S tendered his resignation due to personal health issues. In his resignation letter, he mentioned the need to undergo treatment for health problems that have been aggravating over the past few weeks.

Regulatory Compliance

The resignation will result in Mr. Phaninder Nath P S ceasing to be Key Managerial Personnel under Section 203 of the Companies Act, 2013, and Senior Management Personnel under Regulation 30(5) of the SEBI Listing Regulations. This change affects his role in determining materiality of events or transactions for required stock exchange disclosures.

Vivimed Labs has fulfilled its regulatory obligations by notifying both BSE (Code: 532660) and NSE (Symbol: VIVIMEDLAB) about this development. The company provided all required details as per SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Management Transition

In his resignation letter, Mr. Phaninder Nath P S expressed gratitude to the Board for their support and cooperation during his tenure. He wished the company continued success in its future endeavors. The resignation letter was signed by Company Secretary Yugandhar Kopparthi on behalf of Vivimed Labs Limited.

The company has indicated it will initiate necessary filings with stock exchanges and the Ministry of Corporate Affairs as per applicable regulations. Vivimed Labs Limited, incorporated in 1988, operates from its registered office in Kolhar Industrial Area, Bidar, Karnataka, with corporate offices in Hyderabad, Telangana.

Vivimed Labs Limited has announced that its Board of Directors will meet on February 13, 2026, to review and approve the company's third quarter financial results for FY26. The pharmaceutical company made this announcement in compliance with regulatory requirements, notifying both major stock exchanges about the scheduled board meeting.

Meeting Details and Agenda

The board meeting is scheduled to take place on Friday, February 13, 2026, at the company's Hyderabad office. The primary agenda includes consideration and approval of unaudited financial results covering both standalone and consolidated performance metrics.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. Vivimed Labs communicated this information to both BSE Limited and National Stock Exchange of India Ltd, where the company's shares are traded under the codes BSE - 532660 and NSE - VIVIMEDLAB respectively.

Company Information

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, while maintaining its corporate office in Hyderabad, Telangana. The company secretary Yugandhar Kopparthi signed the official communication to the stock exchanges. The meeting agenda also includes consideration of any other items that may be brought before the board during the session.

Investors and stakeholders will be awaiting the financial results that will provide insights into the company's performance for the quarter and nine months ending December 31, 2025.